Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol

Reproductive BioMedicine Online

Volumn 18, Issue 1, 2009, Pages 15-20

  Lainas, Trifon G ^a,c   Sfontouris, I A ^a   Zorzovilis, I Z ^a   Petsas, G K ^a   Lainas, G T ^a   Iliadis, G S ^a   Kolibianakis, E M ^b  

^a Eugonia Iatriki Erevna IVF Centre   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c HELENA VENIZELOU HOSPITAL   (Greece)

Author keywords

Blastocyst cryopreservation; GnRH antagonist; Long protocol; Luteolysis; OHSS

Indexed keywords

ARVECAP; CHORIONIC GONADOTROPIN; ENOXAPARIN; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; RECOMBINANT FOLLITROPIN; TRIPTORELIN; UNCLASSIFIED DRUG; UREA;

ARTICLE; ASCITES FLUID; BLASTOCYST; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; ECHOGRAPHY; FEMALE; FERTILIZATION IN VITRO; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; LUTEOLYSIS; OOCYTE RETRIEVAL; ORGAN SIZE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; TREATMENT DURATION; UREA BLOOD LEVEL;

EID: 58649085913     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60419-1     Document Type: Article

References (41)

1. Abdalla HI, Ah-Moye M, Brinsden P et al. 1987 The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in-vitro fertilization program. Fertility and Sterility 48, 958-963.
2. Aboulghar MA, Mansour RT, Amin YM et al. 2007 A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reproductive BioMedicine Online 15, 271-279.
3. Aboulghar MA, Mansour RT 2003 Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update 9, 275-289.
4. Abramov Y, Elchalal U, Schenker JG 1999 Severe OHSS: an 'epidemic' of severe OHSS: a price we have to pay? Human Reproduction 14, 2181-2183.
5. Al-Inany HG, Abou-Setta AM, Aboulghar M 2007 Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reproductive BioMedicine Online 14, 640-649.
6. Asch RH, Ivery G, Goldsman M et al. 1993 The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Human Reproduction 8, 1015-1020.
7. Asimakopoulos B, Nikolettos N, Nehls B et al. 2006 Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertility and Sterility 86, 636-641.
8. Barash A, Weissman A, Manor M et al. 1998 Prospective evaluation of endometrial thickness as a predictor of pituitary down-regulation after gonadotropin-releasing hormone analogue administration in an in vitro fertilization program. Fertility and Sterility 69, 496-499.
9. Choi J-H, Gilks CB, Auersperg N, Leung PCK 2006 Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type-I GnRH receptor during follicular development in the human ovary. Journal of Clinical Endocrinology and Metabolism 91, 4562-4570.
10. Dahl Lyons CA, Wheeler CA, Frishman GN et al. 1994 Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Human Reproduction 9, 792-799.
11. D'Angelo A, Amso NN 2002 Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction 17, 2787-2794.
12. Delvigne A, Rozenberg S 2002 Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. International Journal of Fertility and Women's Medicine 47, 211-226.
13. Driscoll GL, Tyler JP, Hangan JT et al. 2000 A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Human Reproduction 15, 1305-1310.
14. Endo T, Honnma H, Hayashi T et al. 2002 Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Human Reproduction 17, 2548-2551.
15. Engmann L, Siano L, Schmidt D et al. 2006 GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reproductive BioMedicine Online 13, 639-644.
16. Fineschi V, Neri M, Di Donato S et al. 2006 An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. International Journal of Legal Medicine 120, 293-299.
17. Griesinger G, Kolibianakis EM, Papanikolaou EG et al. 2007 Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertility and Sterility 88, 616-621.
18. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM 2006 GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reproductive BioMedicine Online 13, 628-638.
19. Gustofson RL, Larsen FW, Bush MR, Segars JH 2006 Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome. Fertility and Sterility 85, 251-254.
20. Itskovitz J, Boldes R, Levron J et al. 1991 Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertility and Sterility 56, 213-220.
21. Kolibianakis EM, Kalogeropoulou L, Griesinger G et al. 2007 Among patients treated with FSH and GnRH analogues for in-vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and metaanalysis. Human Reproduction Update 13, 445-452.
22. Lainas TG, Sfontouris IA, Zorzovilis IZ et al. 2007 Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reproductive BioMedicine Online 15, 408-412.
23. Lainas T, Petsas G, Stavropoulou G et al. 2002 Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Fertility and Sterility 78, 529-533.
24. Liebermann J, Tucker MJ 2006 Comparison of vitrification and conventional cryopreservation of day 5 and day 6 blastocysts during clinical application. Fertility and Sterility 86, 20-26.
25. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN 1995 Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. Journal of Clinical Endocrinology and Metabolism 80, 430-434.
26. Navot D, Bergh PA, Laufer N 1992 Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility 58, 249-261.
27. Orvieto R, Rabinson J, Meltzer S et al. 2006 Substituting HCG with GnRH agonist to trigger final follicular maturation - a retrospective comparison of three different ovarian stimulation protocols. Reproductive BioMedicine Online 13, 198-201.
28. Pride SM, Yuen BH, Moon YS, Leung PC 1986 Relationship of gonadotropin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. American Journal of Obstetrics and Gynecology 154, 1155-1160.
29. Queenan JT Jr., Veeck LL, Toner JP et al. 1997 Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Human Reproduction 12, 1573-1576.
30. Rizk B, Aboulghar MA 1999 Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P (ed.) In-Vitro Fertilization and Assisted Reproduction. The Parthenon Publishing Group, New York, London, pp. 131-155.
31. Rizk B, Smitz J 1992 Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Human Reproduction 7, 320-327.
32. Rizk B, Aboulghar M, Smitz J, Ron-El R 1997 The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Human Reproduction Update 3, 255-266.
33. Semba S, Moriya T, Youssef EM, Sasano H 2000 An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion. Pathology International 50, 549-552.
34. Sher G, Zouves C, Feinman M, Maassarani G 1995 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Human Reproduction 10, 3107-3109.
35. Shoham Z, Weissman A, Barash A et al. 1994 Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in-Vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertility and Sterility 62, 137-142.
36. Taylor PD, Hillier SG, Fraser HM 2004 Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. Journal of Endocrinology 183, 1-17.
37. The European Recombinant LH Study Group 2001 Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in-vitro fertilization procedures: results of a multicenter double-blind study. Journal of Clinical Endocrinology and Metabolism 86, 2607-2618.
38. Tomazevic T, Meden-Vrtovec H 1996 Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome. Journal of Assisted Reproduction and Genetics 13, 282-286.
39. Veeck LL, Bodine R, Clarke RN et al. 2004 High pregnancy rates can be achieved after freezing and thawing human blastocysts. Fertility and Sterility 82, 1418-1427.
40. Wada I, Matson PL, Troup SA et al. 1992a Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. Human Reproduction 7, 962-966.
41. Wada I, Matson PL, Horne G et al. 1992b Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome? Human Reproduction 7, 1090-1093.